secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apellis Pharmaceuticals, Inc. (APLS)
CIK:        0001492422
Form:       8-K
Filed at:   2023-10-05T23:59:59+00:00
Accession:  0001193125-23-251073
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apellis reports preliminary SYFOVRE Q3 revenue ~$74M; total since launch ~$160M
-------------------------------------------------------------------------------

- Approximately $74M in preliminary US net SYFOVRE revenue for Q3 2023; ~$160M total since March 2023 launch.
- More than 100,000 vials (commercial+sample) distributed to date; ~37,000 commercial and 10,000 samples in Q3.
- Permanent J-code effective Oct 1; >95% of Medicare payers now covering SYFOVRE.
- GALE extension study shows up to 45% reduction in nonsubfoveal GA lesion growth at Months 24-30 vs projected sham.
- Estimated retinal vasculitis rate remains rare at 0.01% per injection; 10 confirmed events, 2 suspected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492422/000119312523251073/0001193125-23-251073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492422/000119312523251073/d555980d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-251073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer